What does FDA 510(k) clearance mean?

It is a premarket notification indicating that the device is safe and effective and substantially equivalent to a legally marketed device.

How does this feature impact patient safety?

It enables early detection of opioid-induced respiratory depression, allowing prompt intervention and reducing complications.

Danaher's Masimo Gets FDA Nod for AI Opioid Detection Tool

Masimo, a Danaher company, received FDA 510(k) clearance for an AI-powered opioid-induced respiratory depression detection feature integrated into its Radius VSM wearable continuous patient monitor.

June 25, 2026

2 min read

Source: Simply Wall St.

On June 22, 2026, Masimo, a Danaher (NYSE: DHR) company, announced it received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection feature integrated into its Radius VSM wearable continuous patient monitor.

The Product

The new feature uses advanced AI algorithms to analyze real-time pulse oximetry data, enabling early detection of opioid-induced respiratory depression. It aims to improve patient safety in hospitals by providing clinically actionable alerts before deterioration occurs.

Pricing and Availability

Masimo has not yet disclosed pricing or commercial launch details for the new feature. It is expected to be available as a software update for existing Radius VSM devices.

Competition

Danaher faces competition from companies like Medtronic and GE Healthcare in smart patient monitoring. However, this feature may give it a competitive edge by integrating AI for critical condition detection.

Potential Impact on Danaher

The clearance strengthens Danaher's position in medtech and expands its product portfolio toward AI-driven solutions. It could boost demand for Radius VSM and open new markets in hospitals focused on patient safety.

Frequently Asked Questions

A wearable continuous patient monitor from Masimo that measures pulse oximetry and other vital signs.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.